Christa Müller

Prof. Christa Müller

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
BFBertil B. Fredholm
Bertil B. Fredholm
AIAdriaan P. Ijzerman
Adriaan P. Ijzerman
Kenneth A. JacobsonKenneth A. Jacobson
Kenneth A. Jacobson
JLJoel Linden
Joel Linden
CMChrista Müller
Christa Müller
In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major changes in the recommendations. However, there have been so many other developments that an update is needed. The fact that the structure of one of the adenosine receptors has recently been solved has already led to new ways of in silico screening of ligands. The evidence that adenosine receptors can form homo- and heteromultimers has accumulated, but the functional significance of such complexes remains unclear. The availability of mice with genetic modification of all the adenosine receptors has led to a clarification of the functional roles of adenosine, and to excellent means to study the specificity of drugs. There are also interesting associations between disease and structural variants in one or more of the adenosine receptors. Several new selective agonists and antagonists have become available. They provide improved possibilities for receptor classification. There are also developments hinting at the usefulness of allosteric modulators. Many drugs targeting adenosine receptors are in clinical trials, but the established therapeutic use is still very limited.

25 April 2016 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
EMEnas M. Malik
Enas M. Malik
CMChrista Müller
Christa Müller

16 September 2021 in British Journal of Pharmacology
Verified
Journal Article
Open access
SASteve Alexander
Steve Alexander
ACArthur Christopoulos
Arthur Christopoulos
ADAnthony P Davenport
Anthony P Davenport
EKEamonn Kelly
Eamonn Kelly
AMAlistair Mathie
Alistair Mathie
RYRichard D. Ye
Richard D. Ye
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found athttp://onlinelibrary.wiley.com/doi/bph.15538. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

23 March 2014 in Nature
Verified
Journal Article
Closed access
PDF file
KZKaihua Zhang
Kaihua Zhang
JZJin Zhang
Jin Zhang
ZGZhan-Guo Gao
Zhan-Guo Gao
DZDandan Zhang
Dandan Zhang
LZLan Zhu
Lan Zhu
QZQiang Zhao
Qiang Zhao

1 May 2011 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
CMChrista Müller
Christa Müller
Kenneth A. JacobsonKenneth A. Jacobson
Kenneth A. Jacobson

14 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
RSRamona Schrage
Ramona Schrage
ASAnna-Lena Schmitz
Anna-Lena Schmitz
EGEvelyn Gaffal
Evelyn Gaffal
SASuvi Annala
Suvi Annala
SKStefan Kehraus
Stefan Kehraus
EKEvi Kostenis
Evi Kostenis
Despite the discovery of heterotrimeric αβγ G proteins ∼25 years ago, their selective perturbation by cell-permeable inhibitors remains a fundamental challenge. Here we report that the plant-derived depsipeptide FR900359 (FR) is ideally suited to this task. Using a multifaceted approach we systematically characterize FR as a selective inhibitor of Gq/11/14 over all other mammalian Gα isoforms and elaborate its molecular mechanism of action. We also use FR to investigate whether inhibition of Gq proteins is an effective post-receptor strategy to target oncogenic signalling, using melanoma as a model system. FR suppresses many of the hallmark features that are central to the malignancy of melanoma cells, thereby providing new opportunities for therapeutic intervention. Just as pertussis toxin is used extensively to probe and inhibit the signalling of Gi/o proteins, we anticipate that FR will at least be its equivalent for investigating the biological relevance of Gq.